Phase 1

Phase 2

Phase 3

SHINE and SEQUEL Studies Ongoing

In Collaboration with the Alzheimer's Clinical Trials Consortium (ACTC)

Phase 2 initiation 2H 2021*

Phase 2 initiation 2H 2021*

Including Parkinson's disease and DLB

* Subject to discussion with FDA, the clinical development programs will begin with Phase 2 studies supported by the Phase 1 AD studies

Disruptions in Cellular Damage Response Drive Neurodegenerative Diseases
Alzheimer’s and Parkinson’s diseases and other neurodegenerative brain and eye disorders are caused by the age-related buildup of proteins such as beta amyloid (Aβ) and α-synuclein. Under normal conditions, cellular damage responses trigger the removal of these proteins before they are allowed to accumulate and aggregate into more toxic forms. However, in many neurodegenerative diseases, the damage response is disrupted, allowing the formation of toxic proteins, which in turn leads to damage and eventual loss of the neurons responsible for cognition in Alzheimer’s disease, cognitive and motor function in Parkinson’s disease, and sight in dry AMD.
Lead Candidate:

Cognition has identified several compounds that bind to a receptor that regulates the cellular damage response and have shown potential in the treatment of Alzheimer’s and Parkinson’s diseases. The company’s lead candidate, CT1812, is a first-in-class, orally dosed and highly brain penetrant small molecule that is being assessed as a treatment for mild-to-moderate Alzheimer’s disease. Several studies designed to assess the safety, efficacy and mechanism of action of CT1812 are underway and planned.

Beginning in 2021, Cognition intends to study CT1812 in indications beyond Alzheimer’s disease, including dry AMD.

Scroll to Top